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A simplistic approach was conducted to manufacture novel paclitaxel (PTX) loaded protransfersome tablet 
formulations for pulmonary drug delivery. Large surface area presented by pulmonary system offer better target 
using anti-cancer drug deposition for localized effect in the lungs. Protransfersomes are dry powder 
formulations, whereas transfersomes are liquid dispersions containing vesicles generated from 
protransfersomes upon hydration. Protransfersome powder formulations (F1 – F27) (referred as Micro 
formulations based on transfersomes vesicles size post hydration) were prepared by employing phospholipid 
(Soya phosphatidylcholine (SPC)), three different carbohydrate carriers (Lactose monohydrate, LMH; 
Microcrystalline cellulose, MCC; and Starch), three surfactants (i.e. Span 80, Span 20 and Tween 80) in three 
different lipid phase to carrier ratios (i.e. 1:05, 1:15 and 1:25 w/w), with the incorporation of PTX as a model 
drug. Hydrophobic chain of SPC may enhance PTX solubility as well as its accommodation to improve 
entrapment and delivery via transfersome vesicles to the target site. Out of the 27 Micro protransfersome 
formulations, PTX-loaded LMH powder formulations F3, F6 and F9 (i.e. 1:25 w/w lipid phase to carrier ratio) 
exhibited an excellent powder flowability via angle of repose (AOR) and good compressibility index due to the 
smaller and uniform particle size and shape of LMH. Following hydration, these formulations also showed 
smaller volume median diameter (VMD) in micrometres (5.65 ± 0.85 – 6.76 ± 0.61 µm) and PTX entrapment of 
93 – 96%. Hydrated transfersome formulations (F3, F6 and F9) were converted into Nano size via probe 
sonication and referred as Nano formulations. These Nano formulations were converted into dry powder via 
spray drying (SD) (F3NSD, F6NSD and F9NSD) or freeze drying (FD) (F3NFD, F6NFD and F9NFD). Post 
manufacture of protransfersome tablets (i.e. 9 formulations), quality control tests were conducted in accordance 
to British Pharmacopeia (BP). Only Micro formulations protransfersome tablets (i.e. F3, F6 and F9) passed the 
uniformity of weight test, exhibited high crushing strength and tablet thickness when compared to SD or FD 
protransfersome tablets. Micro protransfersome formulations (i.e. F3, F6 and F9) into tablets demonstrated 
shorter nebulization time and high output rate using Ultrasonic nebulizer as compared to Vibrating mesh 
nebulizer (i.e. Omron NE U22). Based on formulations, characterizations and nebulizer performance; Micro 
protransfersome tablet formulations F3, F6 and F9 (i.e. 1:25 w/w) and Ultrasonic nebulizer was found to be a 
superior combination with enhanced output efficiency. Moreover, PTX-loaded F3, F6 and F9 tablet formulations 
(10%) were identified as toxic (60, 68 and 67% cell viability) to cancer MRC-5 SV2 (i.e. immortalized human 
lung cells) while safe to MRC-5 (normal lung fibroblast cells) cell lines. 
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1. INTRODUCTION
PTX is one of the most widely investigated anti-cancer agent; possessing high anti-tumour activity against lung, 
breast, neck, head and ovarian cancers, as well as Kaposi’s sarcoma (McGuire et al., 1989, Spencer and 
Faulds, 1994, He et al., 2003). PTX reduces the critical concentration of microtubules protein which are essential 
for microtubule assembly, a crucial aspect of cancerous cell growth (Orr et al., 2003). PTX also prevents 
angiogenesis-related cell migration and proliferation, in addition to collagenase secretion. PTX possesses low 
water solubility, in addressing this through the addition of excipients (which aid in water solubility in intravenous 
formulation), incidence of side effects are notable, including; diarrhoea, nausea, vomiting, hypersensitivity 
reactions and neutropenia (Gelderblom et al., 2001). These unwanted reactions originating from PTX 
formulations can be diminished when phospholipid and surfactants are employed in combinations, in the form 
of transfersome formulations. These inherently improve solubility (due to the presence of hydrocarbon chains). 
The term “Transfersome” is a combination of Latin and Greek words, with the derived meaning of “carrying 
body” (Bhushan Rajendra and Nayan Ashok, 2017). Transfersomes are also referred to as ultradeformable 
vesicles, possessing an aqueous core suitable for the entrapment of hydrophilic drugs. This core is surrounded 
by concentric bilayers of phospholipid in which hydrophobic drugs may be successfully entrapped. The 
phospholipid component of transfersomes is associated with stability problems (i.e. aggregation, fusion and 
leakage of drugs from the vesicles) (Khan et al., 2016). Dry powder formulations of transfersomes 
(protransfersomes) have been investigated as a means to increase the stability of the vesicle formulation.  
Succinctly, these dry formulations are comprised of a thin lipid film (e.g. a mixture of phospholipid, surfactant, 
drug and with or without cholesterol) deposited over carbohydrate carrier particles (e.g. sucrose, sorbitol or 
mannitol). Transfersomes are generated from protransfersome by a simple hydration method (Subramanian et 
al., 2016). However, maintaining the formulation in powder form is highly challenging due to bulk associated 
with powder formulations, difficulty in large scale manufacture, and health risks associated with the inhalation 
of ultrafine particles present in powder formulations (EPA, 2013). Thus, the compression of powders into tablet 
form is appealing, offering number of select advantages, including; ease of large scale manufacturing, handling 
and packaging. 
With respect to pulmonary disease states, inhalation of vesicles via nebulization enhances residence time of 
API’s in the lungs, potentially enhancing therapeutic effect without inducing significant systemic side effects 
(Khan et al., 2016). Lipid-based vesicles may be deposited into artificial lung model (e.g. a Two Stage Impinger 
(TSI)) via Air-jet, Ultrasonic or Vibrating mesh nebulizers. Air-jet nebulizer may damage the delicate vesicles 
due to compressed gas passing through venture (0.3 – 0.7 mm in diameter) forming a jet of formulation liquid 
in the nebulizer, followed by collapsing into small droplets due to surface tension (McCallion et al., 1996, Aulton 
and Taylor, 2018b). Ultrasonic nebulizer produces high frequency vibrations via piezoelectric crystals, producing 
aerosol droplets. However, these nebulizers are associated with heat production, which may damage 
thermolabile compounds (Leung et al., 1996, Taylor and McCallion, 1997). Vibrating mesh nebulisers possess 
perforated plate containing aperture of specific diameters in micrometres, and therefore aerosols of a specific 
size are produced and delivered (Aulton and Taylor, 2018b). However, vesicle damage is possible during 
aerosol formation when this nebulizer is employed (McCallion et al., 1996, O'Callaghan and Barry, 1997). It is 
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evident that there are a mixture of benefits and pitfalls when employing nebulizers. In spite of this, the flexibility 
and resilience exhibited by transfersomes provides scope for investigation as nebulized formulations.  
This study aims to develop and determine PTX-loaded protransfersome powder formulations via a slurry-based 
method, followed by compression into novel PTX-loaded protransfersome tablets. Initially, 27 protransfersome 
powder formulations using one phospholipid (SPC), three carbohydrate carriers (LMH, MCC and Starch), three 
surfactants (Span 80, Span 20 and Tween 80) and three lipid phase to carrier ratios (1:05, 1:15 and 1:25 w/w) 
were prepared and investigated to find the best formulation with high powder flowability. Post tablet 
manufacturing, quality control tests were performed according to BP in order to assess the quality of tablets via 
uniformity of weight, hardness (i.e. crushing strength), thickness and disintegration time. Selected PTX-loaded 
protransfersome tablets were aerosolized using two different nebulizers to generate inhalable aerosol droplets. 
The performance of tablet formulations and nebulizer types were characterized with the help of nebulization 
time, sputtering time, mass output and output rate of aerosols. The cytotoxicity of transfersome vesicles 
hydrated from protransfersome tablets were further investigated in MRC-5 (i.e. normal lung fibroblast cells) and 
MRC-5 SV2 (i.e. cancer immortalized lung cells) cell lines. This is the first study where PTX-loaded 
protransfersome tablets were employed for aerosolization as well as cell lines study. 
2. MATERIALS AND METHODS
2.1. Materials 
Cholesterol, Span 20, Span 80, Tween 80 and Fetal bovine serum (FBS) were purchased from Sigma-Aldrich, 
UK. Lactose Monohydrate (LMH), Microcrystalline Cellulose (MCC; Avicel PH 12), and Starch (Starch-150) 
were procured from VWR (BDH Prolab), UK. Analar grade acetonitrile, methanol, absolute ethanol, deionized 
water and Millipore filters (10KD) were obtained from Fischer Scientific, UK. Soya Phosphatidylcholine (SPC; 
Lipoid S-100, 94% purity) was acquired from Lipoid, Steinhausen, Switzerland. Paclitaxel was purchased from 
ChemieTek, Indianapolis, USA. The Vibrating mesh nebulizer (i.e. Omron NE U22)  was purchased from Omron 
Healthcare UK Ltd, UK. The Ultrasonic nebulizer was procured from Uniclife Healthcare LTD, UK. Dulbecco's 
Modified Eagle Medium (DMEM) with high glucose, TryplTrypLE™ Express Enzyme (1X), with phenol red, and 
AlamarBlue™ cell viability reagent were bought from Gibco, Thermofisher, UK. MRC-5 (ECACC 05090501) and 
MRC-5 SV2 (ECACC 84100401) cell lines were obtained from Public Health England (Salisbury, UK). 
2.2. Preparation of Paclitaxel loaded protransfersomes 
Protransfersomes were prepared using three different carbohydrate carriers: Lactose monohydrate (LMH), 
microcrystalline cellulose (MCC) or Starch via a Slurry method (Khan et al., 2015). Three surfactants were 
employed, based on their hydrophilic-lipophilic balance (HLB) values Span 80 (HLB = 4.3), Span 20 (HLB = 8.6) 
and Tween 80 (HLB = 15) (Bnyan et al., 2018). The formulation lipid phase (250 mg) was comprised of 15% of 
surfactant (37.50 mg), and 85% of the combination of SPC and cholesterol (212.50 mg) in a 1:1 molar ratio (i.e. 
141.67 mg of SPC and 70.83 mg of cholesterol). Paclitaxel (PTX) was employed at a 2 mole% concentration to 
lipid phase (i.e. 7.74 mg of PTX for Span 80, 8.10 mg of PTX for Span 20 and 6.75 mg of PTX for Tween 80). 
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Moreover, three different lipid phase to carrier ratios were trialed for protransfersomes formulations i.e. 1:05, 
1:15 or 1:25 w/w. 
In the preparation of LMH-based protransfersomes in a 1:05 w/w lipid phase to carrier ratio formulation, LMH 
(1250 mg) was placed in a 100 ml of round bottom flask (RBF). Lipid phase (250 mg) and PTX were dissolved 
in absolute ethanol (20 ml). This alcoholic solution was then poured over LMH in a RBF to make a slurry. A 
rotary evaporator (Buchi Rotavapor R-114, Buchi, Switzerland) equipped with a vacuum pump (Buchi Vac V-
501) and  water bath set at 45°C, was used to create a negative pressure to evaporate organic solvent from the 
RBF; with a rotation speed of 270 rpm for an approximately 1 h. Following this period, negative pressure was 
released and the dry powder protransfersomes harvested and stored at -18°C for subsequent studies. This 
protocol/procedure was followed and repeated in order to prepare 27 protransfersome powder formulations 
(Table 1).  
2.3. Flow properties of protransfersome formulations 
Each coarse carbohydrate carrier (i.e. LMH, MCC and Starch) and protransfersome formulation (F1 – F27) were 
tested for their flow properties via angle of repose (AOR) and consolidation index. The AOR method was 
employed using a fixed funnel method (Aulton and Taylor, 2018a), where a funnel was clamped with a stand 
and the lower end of the funnel adjusted at  circa 2 – 4 cm distance from the table surface. The weight of the 
powder was recorded (10 g) and poured into a funnel, where a uniform cone was formed (USP., 2015, BP., 
2016b). Any asymmetric cone formation was discarded and the measurements were repeated again. The height 
of the powder cone (from base to the tip of the cone formed) and diameter of the powder base was measured. 
This procedure was repeated to determine AOR values for all three coarse carbohydrate carriers as well as 
protransfersome formulations (i.e. F1 – F27) with the help of following equation; 
°  
For Carr’s consolidation index, a graduated cylinder of 25 ml with 1 ml increments was used (USP., 2015, BP., 
2016c). Coarse carbohydrate carrier or protransfersome powder formulations (10 g) were transferred to the 
cylinder, followed by 2 – 3 gentle taps on a hard surface to ensure a uniform powder level in the cylinder. The 
initial volume (V0) of powder in the cylinder was noted and the cylinder was then adjusted or set in an automated 
controlled tapping tapped density tester (Agilent technologies, USA). The height (14 ± 2 mm) and tapping rate 
(100 ± 15 tapes/min for 5 min) of the cylinder were set. After complete tapping, the final volume (Vf) of the 
powder in the cylinder was recorded and Carr’s consolidation index was determined with the help of an equation 
using initial volume and final tapped volume of powder in the cylinder (Carr, 1965). This experiment was 




2.4. Characterisation of particles size and zeta potential of transfersome vesicles 
Protransfersome powders were hydrated (150 mg/5 ml) in deionised water to form transfersome suspensions, 
followed by an annealing period of 1 h. Annealing of hydrated transfersome is achieved by leaving the 
transfersomes without disruption/shaking at a temperature above the phase transition of the lipid. Annealing 
may help to overcome the possible structural defects of the transfersome bilayers (Lawaczeck et al., 1976). 
Transfersome particle size also known as volume median diameter (VMD) and poly dispersity index (PDI also 
referred to as SPAN) were measured using laser diffraction (Malvern Mastersizer 200, Malvern Instruments, 
UK). This instrument was used to measure particle size in a micrometre range. 
Zeta potential of transfersome particles were determined using a Zetasizer Nanoseries (Malvern Instruments 
Ltd., UK) employing Laser Doppler Velocimetry (LDV) via electrophoretic mobility in dispersion medium. 
Transfersomes in the nanometre range were measured using dynamic light scattering (DLS) (Zetasizer Nano; 
Malvern Instruments Ltd., UK). 
2.5. Drug entrapment in transfersomes 
Transfersomes were generated from dry protransfersome formulations (150 mg/5 ml), followed by annealing. 
For total drug, 1 ml of the formulation was diluted with methanol and the PTX present was quantified using 
HPLC (Agilent 1200 HPLC instrument, UK). For the unentrapped PTX, 0.5 ml of the formulation was transferred 
to a Millipore filter (10 KD) (Fischer Scientific, UK) and subjected to bench centrifugation (Spectrafuge 24D, 
Labnet International, USA) for 30 min at 15,100 g. This process facilitated the separation of PTX-entrapped 
transfersomes (i.e. the vesicles do not pass through the filter due to their large size) from the unentrapped PTX 
(filtrate, only allowing free PTX to pass). The unentrapped component passing through the filter was diluted with 
methanol to determine the entrapment of PTX in transfersomes using following equation: 
PTX quantification was achieved via HPLC, using acetonitrile and water (80:20% v/v) as a mobile phase with a 
flow rate of 1.2 ml/min and a detection wavelength of 230 nm. Machine temperature was set at 25°C, with an 
injection volume of 10 µl. The HPLC column used was a ODS C-18, 5 µm and 150 mm X 4.6 mm (Agilent 
technology, USA). A calibration curve of PTX (5 – 80 µg/ml) was constructed for the quantification of unknown 
PTX concentration. 
2.6. Morphology studies of protransfersome via scanning electron microscopy and 
transfersome vesicles via transmission electron microscopy 
Scanning electron microscopy (SEM) was employed to investigate the surface morphology of the dry 
protransfersome powder formulations. Whereas, transmission electron microscopy (TEM) was used to examine 
the structure of the transfersomes. For examination using SEM, protransfersome powders was transferred to 
aluminium stubs, followed by an air spray to remove any excessive powder from the stub. The stub samples 
were then coated with a thin layer of gold via an EMITECH K550X Fine Coater (Quorum Technologies, UK) for 
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2 min under vacuum. Protransfersome powders were then examined via SEM (Quanta 200, Netherlands) at 20 
kV and the images at various magnifications were captured. For TEM analysis, a drop of formulation was placed 
on a carbon coated copper grid (400 mesh) (TAAB Laboratories Equipment Ltd., UK), followed by the addition 
of one drop of phosphotungstic acid (i.e. 1% w/v, as negative staining). Transfersomes structure was observed 
with a number of images captured via a Philips CM 120 Bio-Twin TEM (Philips Electron Optics BV, Netherlands). 
 
2.7. Nano sizing of transfersome vesicles formulations followed by spray drying or freeze drying 
Upon investigation of F1 – F27 protransfersome powder formulations, a range of formulations were selected 
based on the aforementioned characteristics (AOR, compressibility index, VMD, SPAN, zeta potential and 
entrapment efficiency). Transfersome suspensions post-hydration and annealing were analysed in terms of size 
via a Malvern Mastersizer. Transfersome suspensions (vesicles within the micrometre size range) were reduced 
into the nanometre size range with the help of probe sonication (Q125 Qsonica, USA) and referred as Nano 
formulations. Probe sonication was employed for 10 min with a higher amplitude intensity (i.e. 80%).The 
resultant Nano transfersome vesicles suspensions  were converted into dry powders via spray drying (i.e. spray 
dried nano; SDN) and freeze drying (i.e. freeze dried nano; FDN) formulations. 
For spray drying (SD), Nano transfersome vesicles suspensions were fed into the Büchi Mini Spray Dryer B-
290 connected with high performance cyclone (Büchi Laboratories, Switzerland). Atomization of transfersome 
suspensions was conducted using a 0.7 mm nozzle. Outlet temperature was set at 100°C (i.e. inlet temperature 
of 50 ± 3°C) with a feed rate of 5 – 6 ml/min. Aspiration and atomizing air flow rate was adjusted to 100% and 
400 L/h respectively. Transfersome suspensions were agitated (with the help of magnetic stirrer) prior to feeding 
into the spray drier apparatus in order to yield uniform dry particles. The formed spray dried powders were 
collected from the collecting vessel and stored in a seal airtight bottle (100 ml). Dry powders were stored in 
airtight containers in a desiccator for further studies.  
For freeze drying (FD), Nano transfersome suspensions were poured into a 100 ml glass bottle and placed in a 
freezer (Indesit, UK) overnight in order to form a solid frozen mass in bottle. Following this process, the frozen 
sample was then stored in an electronic freeze dryer (Beijer Electronics, Spain) (overnight) in order to determine 
the dry mass of protransfersome powders. These powder formulations were stored in airtight bottles (100 ml) 
in a desiccator for further studies. The same procedure of spray drying (SD) and FD was repeated for all selected 
formulations. 
Production yield was calculated (formula) as the weight of the final product with respect to the total weight of 
starting materials (i.e. protransfersome powder weight prior hydration) used in formulation. Where W1 is the final 
weight of powder formulation collected from the collecting vessel of spray drying and W2 is the initial weight of 
starting material used for protransfersome powder formulation. 
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2.8. Manufacturing of protransfersome tablets 
A Stylcam 2000R compaction simulator tabletting machine (Medelpharm, France) was employed for the 
manufacture of selected protransfersome powder formulations into tablets, ranging in weight from 80 to 250 mg. 
A 7 mm flat punch and die set was used in order to compress protransfersome powders into protransfersome 
tablets and the filling height was adjusted to 8 mm. An average compression force of 10 kN was used with a 
manufacturing speed of 10 tablets per min. A temperature of 17°C and relative humidity of 40% was maintained 
throughout the manufacturing process.  
 
2.9. Quality control tests of protransfersome tablets 
 Protransfersome tablets were characterized using standard quality control tests including; weight uniformity, 
crushing strength, thickness and disintegration tests. These tests were conducted in order to assess their pass 
or fail criteria on the basis of BP. 
In the weight uniformity of protransfersome tablet test, 20 randomly selected tablets were weighed individually 
from each batch using a calibrated balance (PI-225DA Denver Instruments, Germany). The average weight and 
the standard deviation were recorded (BP., 2016d). 
A hardness tester (Dr Schleuniger/ Pharmatron, USA) was used to find the crushing strength of the 10 randomly 
selected tablets from a batch of protransfersome tablets. Before the test, the hardness tester was calibrated 
and the crushing strength of the tablets measured in newtons. 
For thickness testing, again 10 tablets were randomly selected from a batch of tablets with the help of a digital 
vernier calliper (Copley Scientific, UK). Tablets thickness was measured in millimetres (mm). Where the tablet 
diameter is lower than 12.55 mm a tolerance acceptance level of ±5% is inferred; whereas if the tablet thickness 
is greater than 12.55 mm, the acceptance level is ±3% (Lachman et al., 1986). 
In disintegration testing, 6 randomly selected tablets were transferred to the basket-rack assembly of a 
disintegration tester (PTZ Pharma test instruments, Germany). A beaker (1000 ml) was previously filled with 
circa 800 – 900 ml of deionised water as the disintegration medium, and water bath was adjusted at 37°C. 
Tablets in the basket-rack assembly were immersed in the medium and agitated until complete disintegration 
was achieved (BP., 2016a).  
 
2.10. In-vitro studies of protransfersome tablet formulations via nebulization 
Two nebulizers, Vibrating mesh and Ultrasonic were employed in aerosolization studies in the in-vitro artificial 
lung model also known as Two Stage Impinger (TSI) (Copley Scientific, UK). TSI is comprised of two stages; 
the upper stage (i.e. representing the upper part of the respiratory tract) and the lower stage (i.e. representing 
the lower part of respiratory tract). The cut-off aerodynamic diameter between the upper stage and lower stage 
is 6.4 µm. For the collection of aerosol in the TSI, 7 ml deionised water was placed in the upper stage and 30 
ml in the lower stage respectively. After assembling the parts of TSI, the air flow rate was set at 60 L/min. 
Protransfersome tablets of each selected formulation were hydrated in nebulizer reservoir (i.e. 150 mg/5ml w/v 
ratio) and positioned in front of the mouthpiece of TSI. Nebulization performance was characterized for both 
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nebulizers in terms of nebulization time, sputtering time, mass output (%) and output rate (mg/min) for all 
selected protransfersome tablet formulations. Nebulizer mass output and output rate was measured with the 





2.11. Cell viability assay using transfersome generated from protransfersome tablet formulations 
Normal cells i.e. MRC-5 (normal lung fibroblast cells) and cancer immortalized human lung fibroblast cells MRC-
5 SV2  were used in this study to provide a proof of concept.(Zhu and Gooderham, 2002, Huschtscha and 
Holliday, 1983). These cells were plated into black, flat-bottomed 96-well plates at a density of 1x104 cells/ml 
(90 µl/well), where growth medium Dulbecco's Modified Eagle Medium (DMEM) was used containing Foetal 
Bovine Serum (FBS) of 10%, L-glutamine 1% and antibiotic-antimycotic solution of 1%. MRC-5 and MRC-5 SV2 
cells were then incubated in a humidified atmosphere of 5% of CO2 at 37 °C for 24 h. After 24 h, 96-well plates 
containing MRC-5 and MRC-5 SV2 cells were tested with 70%, 30% and 10% of transfersome suspension 
generated from protransfersome tablets formulation i.e. F3, F6 or F9 (i.e. PTX-free and PTX-loaded formulations 
for comparison). After incubation of 24 h, Alamar Blue (AB) (10%) was added in each well, and again incubated 
for 3 h (in order to quantify cell viability). Post incubation, plates were allowed to cool to room temperature and 
a microplate reader (Epoch, BioTek Instruments Ltd., Swindon, UK) was used for reading plates (fluorescence 
excitation at 545 nm, and emission at 600 nm). The obtained values from formulation F3, F6 or F9-treated wells 
were compared with control wells (i.e. treated with deionised water (DW)). Control values were set at 100% and 
the values of formulation F3, F6 or F9-treated wells were normalized to the control values. 
 
2.12. Statistical analysis 
One-way analysis of variance (ANOVA) or student’s t-test was conducted in order to perform statistical 
assessments of difference (using SPSS software) among more than two groups or two sets of data respectively. 
All values were expressed as a mean ± SD (standard deviation) and a p-value <0.05 was considered as a 
significant difference. All experiments were performed in quadruplets. 
 
3. RESULTS AND DISCUSSION 
3.1. Morphology of carbohydrate carrier using SEM 
SEM was used to examine surface morphology of coarse carbohydrate carriers i.e. LMH, MCC and Starch. 
Upon examination of LMH, the particles were found to be smaller and uniform in size and shape (Figure 1a). 
LMH is typically employed as a filler/diluent in tablet manufacturing, thus these carrier particles offer enhanced 
flowability rolling with ease over each other without offering resistance to the movement and improve die filling, 
  10  
 
and therefore reducing weight variation in tablet manufacturing (Prescott and Barnum, 2000, Aulton and Taylor, 
2018c) (Figure 1a). LMH particles are non-porous and due to their smaller and uniform size and shape, the lipid 
phase is uniformly distributed over these carrier particles during protransfersome formulation (Elhissi et al., 
2011, Khan et al., 2018). 
MCC particles appeared to be irregular and variable in size and shape (Figure 1b). MCC particles were 
composed of both crystalline and amorphous areas, with cellulose fibres tending to aggregate, thus having the 
appearance of round to oblong in shape (Aulton and Taylor, 2018c) (Figure 1b). The difference in morphology 
of these particles may restrict particle flowability, which would ultimately affect die filling during tabletting. 
However, these particles possess good disintegration properties which may help in disintegration and 
dissolution of tablets (Aulton and Taylor, 2018c). 
Starch coarse particles were also observed to be irregular in shape and size (very small to very large particles) 
(Figure 1c). However in terms of morphology, Starch particles shapes were not oblong in shape and therefore 
they appeared to have superior flowability when compared to the oblong MCC particles.  
 
3.2. Flow properties of protransfersome powder via AOR and compressibility index 
Upon analysis of AOR, coarse carbohydrate carriers demonstrated  angles of 10.24 ± 1.22, 18.65 ± 1.55 and 
15.01 ± 1.16° for LMH, MCC and Starch correspondingly, exhibiting excellent flowability in accordance to Carr’s 
index (Carr, 1965) (Table 2). The incorporation or exclusion of PTX in the protransfersome powder formulations 
did not affect the flowability characteristics and therefore values originating from formulations without PTX were 
not included. PTX-loaded LMH protransfersome powder formulations F1 – F9, demonstrated excellent 
flowability (angle between 25 – 30°) (Table 2) (Carr, 1965). However, comparatively lower AOR were noted for 
formulations F3, F6 and F9 (all these formulations manufactured in 1:25 w/w lipid phase to carrier ratios) when 
compared to F1, F2, F4, F5, F8 and F7 powder formulations (prepared in a 1:05 or 1:15 lipid phase to carrier 
ratios) (Table 2). This difference in AOR between protransfersomes is related to the presence of lighter or denser 
lipid phase coatings over carbohydrate carriers (Table 1). The denser lipid phase coating may cause the coated 
powder to agglomerate and therefore resist the free movement of particles stacking upon each other as opposed 
to free flowing (Table3).  
Similar trend of AOR was demonstrated by the MCC-based protransfersome (i.e. F10 – F18) and Starch-based 
protransfersome (i.e. F19 – F27) powder formulations, respectively (Table 2). Overall, the powder formulations 
(F10 – F27) exhibited excellent powder flowability, with flowability and AOR increasing as carbohydrate ratio 
increased. MCC-based protransfersome powder formulations demonstrated comparatively higher angle of 
reposes than starch-based formulations, which may be attributed to the variance in particle size of MCC eliciting 
greater resistance to powder flow. 
Moreover, LMH-based protransfersome powder offered superior flowability due to the smaller and uniform 
particle size, which enhanced flow of LMH particles when compared to MCC or Starch particles (Section 3.1). 
Upon analysis of compressibility index, coarse carbohydrate carriers demonstrated good flowability for LMH, 
compared to fair flowability of Starch and passable flowability of MCC carriers (Table 2) (Carr, 1965). This may 
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be attributed to the carrier morphology of LMH (uniform and smaller particles), when compared to MCC (i.e. 
oblong particles) and Starch (irregular in size and shape particles) (Section 3.1). The aforementioned trend was 
mirrored with respect to compressibility index for the protransfersome powder formulations (F1 – F27). In LMH-
based protransfersome powder formulations (F1 – F9), compressibility index exhibited an excellent flowability 
for F1, F4 and F7 formulations, when compared to good flowability of F2, F3, F5, F6, F8 and F9 (Table 2). 
Significantly (p<0.05) lower values of compressibility index of protransfersome powder was noted for 
formulations with a 1:05 w/w lipid phase to carrier ratio (i.e. F1, F4 and F7), when compared to formulations with 
a 1:25 w/w lipid phase to carrier ratio (F3, F6 and F9) (Table 2). This may be attributed to a denser lipid coat 
over the LMH carriers in the 1:05 w/w ratio formulations. The presence of high lipid content may reduce the 
carrier movement hindering flowability (Table 1). Hence, particles in these formulations (F1, F4 and F7) may 
stick to each other during tapping, and occupy a lower volume, as particles are unable to sediment during 
tapping and maintain their volume in the graduated cylinder. Contrastingly, in protransfersome formulations 
which possessed an elevated proportion of carbohydrate carrier (1:15 or 1:25 w/w), flowability was maintained 
due to the lower degree of particle resistance/stickiness. This trend was also reflected in compressibility index 
values for MCC and starch-based protransfersome powder formulations (Table 2). However some differences 
were observed, with the MCC and starch-based protransfersome powder formulations i.e. 1:05 w/w 
demonstrated fair flowability when compared to passable flowability for 1:25 w/w formulations (Table 2). The 
observed fair and passable flowability may be associated with the particles morphology of MCC p (i.e. oblong 
shaped particles with irregular in size) and starch (irregular size and shape) (Section 3.1).  
Overall, it was identified that compressibility index for formulations with 1:05 w/w demonstrated enhanced 
powder flowability. However, due to high lipid content compared to other formulation ratios (i.e. 1:15 or 1:25 
w/w), the formulation particles elicited resistance to settling, maintaining the powder volume during tapping. 
These results are suggestive that a higher lipid content, would increase particle resistance and deceptively 
enhance flowability. However, in AOR studies, powder formulations with 1:25 w/w lipid phase to carrier ratio 
demonstrated better flowability with low angle and therefore would improve die filling during tablet 
manufacturing. Therefore, protransfersome powder formulations based on LMH were recognised as superior 
when compared to MCC and starch-based formulations. On the basis of the above-mentioned results, LMH-
based protransfersome powder formulations (i.e. F3, F6 and F9) were chosen for further studies 
3.3. VMD, SPAN, zeta potential and entrapment efficiency of PTX in transfersome suspension 
Transfersomes were generated from PTX-loaded protransfersomes in deionised water via hydration followed 
by annealing (Section 2.4). Size, also referred to as volume median diameter (VMD) of transfersomes was 
analysed for all formulations (F1 – F27). Size of transfersomes generated from protransfersomes were within 
the micrometre range, thus these formulations (i.e. F1 – F27) were referred to as Micro protransfersomes 
formulations (Table 2). Upon analysis of VMD, LMH-generated transfersomes (F1 – F9) were significantly 
smaller (p<0.05) when compared to transfersome generated from MCC and Starch-based protransfersomes 
(F10 – F27) (Table 2). Smaller VMD may be associated with their smaller particle size (resulting in a uniform 
distribution of lipid phase over carrier particles) and hypertonic environment caused by LMH, which cause 
shrinkage of lipid vesicle (Lehtonen and Kinnunen, 1994). 
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SPAN values generated from transfersome suspensions (i.e. F1 – F27) exhibited no significant difference 
(p>0.05), with a values ranging from 2.33 ± 0.86 – 4.45 ± 0.99 (Table 2). Transfersome SPAN values were not 
influenced by carrier selection (LMH, MCC and Starch) or lipid phase to carrier ratios (i.e. 1:05, 1:15 and 1:25 
w/w). A similar trend was exhibited in terms of zeta potential values; with no significant difference (p>0.05) 
observed when transfersomes were generated from LMH, MCC or Starch-based protransfersome powder 
formulations (Table 2). 
PTX entrapment efficiency was analysed via HPLC for all (F1 – F27) formulations. The entrapment efficiency of 
PTX found was within the range of 92.04 ± 4.56 – 97.81 ± 3.17% (i.e. F1 – F27) and no significant difference 
(p>0.05) was observed (Table 2). These results are analogous to previous research findings, where the 
entrapment efficiency was as high as 91.65% in lipid-based formulations (You et al., 2017). Similarly, high 
entrapment efficiency circa 89% was also reported by Rane and Prabhakar (2009). Paolino et al. (2012) 
demonstrated 57% of entrapment efficiency using Phosphatidylcholine as a phospholipid, in ultra-deformable 
lipid-based vesicles. High entrapment efficiency of lipophilic PTX may be associated with the long hydrocarbon 
chains of SPC, where PTX molecules may be easily accommodated (Table 2). Additionally, phospholipid 
hydrophobic chains may also enhance the solubilisation of PTX in the concentric bilayers, enhancing drug 
entrapment (i.e. like dissolves like). SPC is a natural phospholipid and it is both biocompatible and 
biodegradable and its toxicity is extremely low (Di Sotto et al., 2018, Nguyen et al., 2017). Furthermore, it offers 
lower phase transition temperature (i.e. – 20 to – 30 °C), which makes this phospholipid more suitable to self-
assemble into vesicles at room temperature or lower (Taylor and Morris, 1995). Surfactant is one of a basic 
component of transfersome/protransfersome formulation, which make vesicles elastic/flexible and therefore 
these vesicles are called flexible or elastic vesicles. Three different surfactants based on their various HLB 
values were used in order to study their effect on size, zeta potential and ability to entrap paclitaxel. However, 
surfactant type did not significantly change the performance of vesicles in terms of size, charge and entrapment 
efficiency as compared to carrier type.  
 
3.4. Initial selection of Micro protransfersome formulations for further testing and tablet 
manufacturing 
Initial investigation and characterization was conducted for all PTX-loaded Micro protransfersome powder 
formulations (i.e. F1 – F27) including; AOR and compressibility index. VMD, SPAN, zeta potential and 
entrapment efficiency of PTX was determined in transfersomes hydrated from protransfersome powder 
formulations (Section 3.2 and section 3.3). Upon analysis of flow properties of protransfersome powder 
formulations, AOR and compressibility index values were indicative that LMH-based protransfersome 
formulations were superior. 
 
3.5. Examination of transfersome vesicles via TEM 
Selected LMH-based protransfersome powder formulations i.e. F3, F6 and F9 were hydrated and their 
morphology were observed. Images captured suggested that transfersomes were spherical in shape and 
appeared to be multilamellar, but the artefacts of TEM including dehydration of sample may have resulted in 
  13  
 
rupture of large multilamellar vesicles whilst the smaller vesicles (oligolamellar vesicles and unilamellar vesicles) 
have survived the stressful environment of TEM.  (Figure 2). These images are confirmative that transfersomes 
formulations were successfully achieved. 
 
3.6. Characterization of spray drying and freeze drying after size reduction 
Upon initial analysis, three protransfersome formulations (F3, F6 and F9) were hydrated to generate Micro 
transfersome vesicles. These micrometre vesicles were then reduced to nanometre (N) size (i.e. F3N, F6N and 
F9N) via probe sonication, followed by their conversion into dry protransfersome powder formulations via spray 
drying (SD) (F3NSD, F6NSD and F9NSD) or freeze drying (FD) (F3NFD, F6NFD and F9NFD). In summary nine 
formulations were taken forward for further studies. 
The initial VMD of Micro size transfersomes i.e. F3, F6 and F9 (5.65 ± 0.85, 6.76 ± 0.61 and 6.46 ± 0.73 µm) 
(Table 2) was significantly (p<0.05) reduced Nano size (254.36 ± 5.64, 458.92 ± 7.78 and 321.56 ± 7.44 nm) 
via probe sonication (Table 3). Following SD, Nano SD protransfersome powder formulations (F3NSD, F6NSD 
and F9NSD) were rehydrated into transfersomes, and no significant difference (p>0.05) was determined in VMD 
before and after spray drying (Table 3). Contrastingly, FD rehydrated protransfersome formulations (F3NFD, 
F6NFD and F9NFD) exhibited significantly (p<0.05) larger VMD when compared to the VMD of transfersome 
suspensions prior to freeze drying (following probe sonication) (Table 3). This increase in VMD of FD 
formulations (Yang et al., 2013, Hua et al., 2003) may be attributed to the formation of crystalline structure of 
water molecules during the freezing phase and therefore may disrupt the vesicle bilayer membrane. Thus, 
following rehydration vesicles may aggregate or fuse together. Upon investigation of PDI and zeta potential 
values, no significant difference (p>0.05) was observed between probe-sonicated transfersomes and 
transfersomes rehydrated following SD and FD (Table 3). 
Production yield of Nano SD transfersome powder was calculated from the formulations collected in the 
collecting vessel of spray drying instrument. Low production yield (i.e. 57.94 ± 2.86 – 63.86 ± 3.69) and no 
significant difference (p>0.05) was observed between F3NSD, F6NSD and F9NSD formulations (Table 3). This 
lower production yield may be attributed to the lower inlet temperature (i.e. 100°C). Low inlet temperatures may 
cause particles to deposit in the cyclone compartment due to poor droplet drying in the drying chamber 
increasing particle adherence to the walls of drying chamber and cyclone compartment (Maa et al., 1997, Maury 
et al., 2005, Imtiaz-Ul-Islam and Langrish, 2009). Powder recovery post spray drying process may also depend 
upon the free flowing properties of powder. High moisture content at low outlet temperature may further causes 
sticking of powder particles to the chamber walls and therefore lower powder output. Contrastingly, a high air 
inlet temperature may increase the production yield (Rathananand et al., 2007), which may be attributed to heat 
energy available in the drying chamber responsible for quick drying of atomized droplet preventing sticking of 
particles to the walls of the spray drier. AOR studies conducted for Nano SD powder formulations (F3NSD, 
F6NSD and F9NSD) exhibited poor flowability (46.65 ± 2.06, 49.68 ± 1.62 and 48.54 ± 1.43°) (Table 3). This 
may be associated with amorphous and crystalline regions of the SD powder and the presence of moisture, 
which may further facilitate particle aggregation. 
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Alternatively, the obtained Nano FD powder formulations (i.e. F3NFD, F6NFD and F9NFD) exhibited a high 
production yield of 93.52 ± 3.12, 93.48 ± 3.62 and 94.76 ± 3.55%, however they were observed to be cohesive 
in form as a solid mass. Regardless of high production yield, the absence of flowability of the powder renders 
the formulation unsuitable for tabletting and was hence eliminated from further studies. 
In summary, initial Micro formulations F3, F6 and F9 as well as Nano SD formulations F3NSD, F6NSD and 
F9NSD were selected for further investigations, demonstrating excellent (13.16 + 0.81, 14.01 + 1.03 and 13.62 
+ 1.14°) (Table 2) to poor (i.e. 46.65 ± 2.06, 49.68 ± 1.62 and 48.54 ± 1.43°) flow properties in terms of AOR 
(Table 3). 
 
3.7. Weight uniformity test of PTX-loaded protransfersome tablet  
PTX-loaded Micro protransfersome tablet formulations F3, F6 and F9 exhibited no significant difference 
(p>0.05) in weight (Table 4). Similarly, no weight variation was recorded between PTX-loaded Nano SD 
protransfersome powders into tablets (Table 4). According to British pharmacopeia (BP), to comply with weight 
variation test, no more than two individual tablets should deviate from the average weight  by more than the 
percentage allowed i.e. ±7.5% (i.e. when tablet weight is between 80 – 250 mg), and none of the tablets should 
deviate by more than twice this percentage (i.e. ±15%) (BP., 2016d). The average weight difference between 
Micro protransfersome tablets (F3, F6 and F9) and Nano SD tablets (F3NSD, F6NSD and F9NSD) formulation 
are significantly different (p<0.05) from each other. This lower weight of Nano SD tablet formulation may be 
attributed to the combination of amorphous and crystalline regions of SD powder (i.e. a hygroscopic powder 
which also possesses moisture due to low outlet temperature during spray drying) which may facilitate powder 
aggregation and therefore impact upon die filling, resulting in lower tablet weight. Moreover, SD powder 
formulations also showed capping due to the sticky nature of SD powders during tabletting, lengthening 
tabletting process. 
With respect to tablet weight uniformity, formulations F3 and F6 exhibited a deviation of two tablets, whereas 
F9 formulations demonstrated a deviation of 1 tablet from the average weight by ±7.5%; these formulations 
matched the acceptance criteria in accordance to BP standards (BP., 2016d). Comparatively, Nano SD 
formulations exhibited a deviation of 5 tablets for each F3NSD and F6NSD formulation, and 6 tablets for F9NSD 
from the average weight by ±7.5% (not more than two tablets should deviate from the average weight) (Table 
4). Thus, these three batches of SD tablets (i.e. F3NSD, F6NSD and F9NSD) failed the weight variation test in 
accordance to BP standards. These results were also substantiated by AOR values for the powder formulations; 
F3, F6 and F9 demonstrated excellent flow properties, whilst poor flow properties were observed for SD 
formulations (i.e. F3NSD, F6NSD and F9NSD) (Table 2 and Table 3). 
  
3.8. Crushing strength of PTX-loaded protransfersome tablet  
Manufactured PTX-loaded Micro protransfersome tablets formulations F3, F6 and F9 demonstrated high 
crushing strength, whilst PTX-loaded Nano SD tablets formulations (F3NSD, F6NSD and F9NSD) exhibited 
reduced hardness. However, hardness of SD tablets was significantly lower (p<0.05) when compared to Micro 
protransfersome tablets formulations (Table 4). High hardness values of F3, F6 and F9 tablets formulations 
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were related to the excellent flow properties (demonstrated by AOR) of the powders, which in turn enhance die 
filling compared to the poor flow properties of SD formulations (F3NSD, F6NSD and F9NSD) (Table 2 and Table 
3). Poor powder flowability may diminish die filling and consequently a lower compression force is used (due to 
low powder volume in die cavity) to compress powder into tablet. The high crushing strength of F3, F6 and F9 
formulations, are indicative that these tablets may be able to withstand transportation and storage. 
 
3.9. Thickness and disintegration of PTX-loaded protransfersome tablet 
Die filling was previously adjusted to 8 mm to accommodate uniform powder filling. PTX-loaded Micro 
protransfersome tablets demonstrated a thickness measurements of 2.62 ± 0.41, 2.58 ± 0.34 and 2.67 ± 0.39 
mm for formulations F3, F6 and F9; with no significant difference upon comparison of the three formulations 
(p>0.05) (Table 4). Similarly, no significant difference (p>0.05) was also observed in tablet thickness amongst 
Nano SD tablet formulations. Interestingly, tablet thickness of protransfersome Micro formulations were 
significantly (p<0.05) higher than Nano SD formulations; this is supported by the excellent and poor flowability 
of the corresponding powder particles (Table 2 and Table 3). Moreover, weight variation tests also demonstrated 
that enhanced powder flow may facilitate complete die filling, as compared to inconsistent die filling 
demonstrated by agglomerated and hygroscopic SD powder formulations. 
Upon investigation of disintegration time, PTX-loaded Micro protransfersome tablets exhibited longer 
disintegration time, which is directly associated with high compression force used to compress powders, also 
substantiated by the high tablet thickness and high crushing strength (Table 4). Contrastingly, low disintegration 
time was demonstrated by Nano SD tablet formulations (Table 4). Upon comparison, significantly higher 
(p<0.05) disintegration time was found for Micro protransfersome tablet formulations when compared to Nano 
SD protransfersome tablets formulations. This lower disintegration time may be attributed to the nature of SD 
powder, which was hygroscopic facilitating water absorption succeeded by quick disintegration. Additionally, 
the lower weight and thickness of SD tablets may also improve tablet disintegration time. According to the BP 
standards, normal tablets should disintegrate within 15 min with no residue remaining in the disintegration 
instrument (BP., 2016a). Consequently, all protransfersome tablet formulations (i.e. F3, F6, F9, F3NSD, F6NSD 
and F9NSD) passed the disintegration test. So novel protransfersome tablets were characterized using various 
quality control tests (i.e. uniformity of weight, crushing test, thickness and disintegration time) in order to identify 
quality of the tablets. The sustained release of paclitaxel and other hydrophobic drugs from vesicles having 
similar composition is established in literature (Najlah et al., 2018, Han et al., 2018). These studies demonstrated 
evidence of release of paclitaxel in a controlled manner. Thus, we proposed that the key limiting step for the 
sustained release to happen is the disintegration of tablet, and that is why we primarily focused on tablet QC 
tests.   
Overall, after conducting quality control tests in accordance to BP; tablets manufactured from Micro 
protransfersome formulations F3, F6 and F9 passed all tests, demonstrating uniform weight variation and tablets 
thickness, high crushing strength and acceptable disintegration time). Whereas, Nano SD tablet formulations 
(i.e. F3NSD, F6NSD and F9NSD) failed the weight uniformity test and demonstrated low crushing strength; thus 
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being eliminated from further studies. Based on these quality control tests, Micro protransfersome tablet 
formulations F3, F6 and F9 were further investigated for nebulization studies.  
 
3.10. Nebulization performance of PTX-loaded protransfersome tablets via Ultrasonic and Vibrating 
mesh nebulizers 
Ultrasonic and Vibrating mesh nebulizers were employed for the nebulization time of transfersome suspensions 
(5 ml) generated from PTX-loaded Micro protransfersome tablet formulations (i.e. F3, F6 and F9). Upon 
analysis, using individual nebulizers (Ultrasonic or Vibrating mesh), no significant difference (p>0.05) was noted 
between F3, F6 and F9 formulations (Table 5). However, nebulization time for the Ultrasonic nebulizer was 
significantly shorter (p<0.05) when compared to the Vibrating mesh nebulizer (Table 5). The lipid phase (i.e. 
SPC and cholesterol in 1:1 molar ratio) and carbohydrate ratio (3250 mg; 1:25 w/w lipid phase to carrier ratio) 
in formulations F3, F6 and F9 may enhance suspension viscosity (Elhissi et al., 2006, Elhissi et al., 2007); thus 
influencing the low energy of atomization used by Omron nebulizers, resulting in a longer nebulization time 
(Ghazanfari et al., 2007). Additionally, the large size of transfersome vesicles may also block the aperture of 
mesh (i.e. Omron nebulizer) and hence lengthen the nebulization time. Ultrasonic nebulizers function on the 
basis of piezoelectric crystal movement, which may be responsible for the formation of aerosols without 
impacting upon transfersome vesicle size and achieving a subsequently short nebulization time. Analogous 
results of shorter nebulization times achieved via Ultrasonic nebulizer was also reported by Mercer (1981) and 
Mc Callion et al. (1996), when compared to Omron nebulizer. 
Similar results were also noted for sputtering time, where a significant difference (p<0.05) was observed 
between Ultrasonic and Vibrating mesh nebulizers (Table 5). It was identified that viscosity of transfersome 
formulation suspension had a significant effect (p<0.05) on the sputtering time, this may be attributed to the 
slow and consistent propagation of formulation through the mesh from the nebulizer reservoir in the Vibrating 
mesh nebulizer (over a long time period). Whereas in Ultrasonic nebulizer, transfersome suspensions stayed in 
the nebulizer (also referred to as residual or dead volume, which may not able to nebulize) may unable to form 
capillary waves followed by fragmentation (mechanism of Ultrasonic nebulizer for aerosolization). As a 
consequence, sputtering time was lengthened to aerosolise the residual volume. Similar results of sputtering 
time were also reported by Steckel and Eskandar (2003). 
In mass output, regardless of complete nebulization time, 100% mass output cannot be achieved as a proportion 
of the formulation remains in the nebulizer reservoir (Clay et al., 1983). A lower mass output was demonstrated 
by Ultrasonic nebulizer when compared to Vibrating mesh nebulizer (Table 5). The lower mass output 
percentage of F3, F6 and F9 by Ultrasonic nebulizer may be attributed to the comparatively high proportion of 
dead volume (Table 5). Contrastingly, higher mass output by Vibrating mesh nebulizer for formulation 
suspension (F3, F6 and F9) may be attributed to the lower proportion of dead volume and longer nebulization 
time. Moreover, a lower dead volume was also reported by Vecellio et al. (2011) as well as Dolovich and Dhand 
(2011) when compared to Ultrasonic nebulizer. The higher mass output via Vibrating mesh nebulizer is in 
agreement with the previous research conducted by Elhissi and Taylor (2005) and Elhissi et al. (2006). Upon 
investigation of output rate, a significant difference (p<0.05) was determined when employing Ultrasonic and 
Vibrating mesh nebulizers. The Ultrasonic nebulizer exhibited an output rate of more than double that of the 
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Vibrating mesh nebulizer for formulations F3, F6 and F9 (Table 5). The lower output rate exhibited by the 
Vibrating mesh nebulizer may be attributed to the viscosity of transfersome suspension (blocking mesh aperture 
and increasing nebulization time). Contrastingly, the Ultrasonic nebulizer was least affected by the viscosity of 
transfersome suspension resulting in high output rate of formulations.  
Overall, on the basis of nebulizer performance, the Ultrasonic nebulizer elicited shorter nebulization times and 
an average of 90% mass output. Whilst comparing to the Vibrating mesh nebulizer, the Ultrasonic nebulizer 
demonstrated approximately a two fold increase in output rate. Thus, the Ultrasonic nebulizer was identified as 
superior in performance when compared to Vibrating mesh nebulizer. 
 
3.11. Cell viability/cytotoxicity studies using transfersome generated from protransfersome tablet 
formulations 
In order to find a quick and simple cell viability study (i.e. proof of principle), MRC-5 (i.e. normal lung fibroblast 
cells) and cancer immortalized human lung fibroblast cells MRC-5 SV2 were employed for the cytotoxicity of 
PTX-free and PTX-loaded in protransfersome tablet formulations (i.e. F3, F6 and F9). MRC-5 SV2 cells are 
basically a transformed version of MRC-5, where MRC-5 cells were transfected with Simian virus SV-40 and 
are thus immortalized (Huschtscha and Holliday, 1983). Non-transformed human lung fibroblasts have a limited 
lifespan when cultured in-vitro. Whereas, MRC-5 SV2 does not deteriorate and their growth do not slow down, 
indicating these cells has a potential for infinite growth (Yang et al., 1992). Moreover, the effect of carcinogenic 
agent were also studied using MRC-5 SV2 immortalized human lung fibroblast cells (as a potential lungs cancer 
cells) (Zhu and Gooderham, 2002). Both MRC-5 and MRC-5 SV2 cells were used for cytotoxicity studies using 
Alamar Blue assay. The effect of PTX-free and PTX-loaded F3, F6 and F9 tablet formulations on the viability of 
MRC-5 and MRC-5 SV2 cells were investigated over 24 h using three different formulations concentrations (i.e. 
70%, 30% and 10%). PTX-loaded transfersome suspension of 70% and 30% generated from protransfersome 
tablets were toxic to MRC-5 SV2 cells but also significantly toxic to the normal MRC-5 cells too (these results 
were excluded and not shown), and therefore formulations with only 10% were plotted against time (24 h) and 
discussed (Figure 3). 
Employing PTX-free tablet formulations, the cell viability of both cells were unaffected (p>0.05), indicating that 
the preparation method and formulations parameters of protransfersomes (i.e. on MRC-5 and MRC-5 SV2) had 
no cytotoxicity effect. Similarly, with 10% of PTX-loaded transfersome suspension generated from 
protransfersome tablets (F3, F6 and F9) were safe in MRC-5 cells (Figure 3). Alternatively, when using them 
(PTX-loaded F3, F6 and F9 formulations), they were noted to be significantly (p<0.05) toxic to MRC-5 SV2 cells, 
exhibiting cell viability of 60, 68 and 67%, respectively. Thus, it was found that PTX-loaded F3, F6 and F9 tablets 
formulation were safe in normal cells but significantly toxic to immortalized cells representing as cancer cells for 
this investigation(Figure 3).  
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4. Conclusions 
In this study 27 PTX-loaded Micro protransfersome powder formulations (referred as Micro formulations based 
on transfersomes vesicles size post hydration) were prepared using onephospholipid, three surfactants and 
three lipid phase to carrier ratios to manufacture PTX-loaded protransfersome tablets. LMH-based Micro 
protransfersome formulations F3, F6 and F9 were selected on the basis of excellent flowability via angle of 
repose, and good compressibility index due to smaller and uniform size and shape of LMH, and thus used for 
tablet manufacturing. The three selected Micro protransfersome formulations were hydrated and Nano sized via 
probe sonication. These formulations were then converted back into dry form via spray drying (SD) or freeze 
drying (FD). Both Nano SD and Nano FD powder formulations showed poor to no flowability via angle of repose. 
Nano SD powder formulations demonstrated poor flowability via angle of repose, and were still included for 
tablet manufacture. However, with no powder flowability exhibited by the Nano FD formulations these were 
eliminated. Amongst the Micro and Nano protransfersome tablets, Micro tablets passed all the quality control 
tests (i.e. uniformity of weight, crushing strength, thickness and disintegration time), whilst Nano SD tablets 
failed the weight uniformity test and showed lower and inconsistent crushing strength and tablet thickness. 
Consequently, Nano formulations were excluded for further studies using medical nebulizers. The Ultrasonic 
nebulizer was found to be efficient in terms of performance for Micro protransfersome tablets as compared to 
Vibrating mesh nebulizer. Cytotoxicity studies exhibited that protransfersome tablet formulations F3, F6 and F9 
(10%) were completely safe in normal cell lines while toxic to cancer cell lines. For future studies, these 
formulations can be further investigated in in-vitro using various lung cancer cells, as well as in-vivo study using 
florescent dye to detect their deposition in animal’s lung by confocal microscopy. Furthermore, drug deposition 
in animal lung can be analyzed via HPLC for quantification. 
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Tables 
Table 1. Protransfersome formulations (F1 – F27) manufactured using three different surfactants (i.e. 
Span 80, Span 20 and Tween 80), with three different carbohydrate carriers (i.e. LMH, MCC and Starch) 
and three different lipid phase to carrier ratios (i.e. 1:05, 1:15 and 1:25 w/w). Lipid phase was prepared 
by using SPC and cholesterol as 1:1 molar ratio (85% w/w) and surfactant (15% w/w), n = 4 
Formulation 
Number 
Phospholipid Cholesterol Carbohydrate 
Carriers 
Surfactants Lipid phase to 
carrier ratio 
(w/w) 
F1 SPC Cholesterol LMH Span 80 1:05 
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F2 SPC Cholesterol LMH Span 80 1:15 
F3 SPC Cholesterol LMH Span 80 1:25 
F4 SPC Cholesterol LMH Span 20 1:05 
F5 SPC Cholesterol LMH Span 20 1:15 
F6 SPC Cholesterol LMH Span 20 1:25 
F7 SPC Cholesterol LMH Tween 80 1:05 
F8 SPC Cholesterol LMH Tween 80 1:15 
F9 SPC Cholesterol LMH Tween 80 1:25 
F10 SPC Cholesterol MCC Span 80 1:05 
F11 SPC Cholesterol MCC Span 80 1:15 
F12 SPC Cholesterol MCC Span 80 1:25 
F13 SPC Cholesterol MCC Span 20 1:05 
F14 SPC Cholesterol MCC Span 20 1:15 
F15 SPC Cholesterol MCC Span 20 1:25 
F16 SPC Cholesterol MCC Tween 80 1:05 
F17 SPC Cholesterol MCC Tween 80 1:15 
F18 SPC Cholesterol MCC Tween 80 1:25 
F19 SPC Cholesterol Starch Span 80 1:05 
F20 SPC Cholesterol Starch Span 80 1:15 
F21 SPC Cholesterol Starch Span 80 1:25 
F22 SPC Cholesterol Starch Span 20 1:05 
F23 SPC Cholesterol Starch Span 20 1:15 
F24 SPC Cholesterol Starch Span 20 1:25 
F25 SPC Cholesterol Starch Tween 80 1:05 
F26 SPC Cholesterol Starch Tween 80 1:15 













Table 2. Coarse carbohydrate carriers alone (Lactose monohydrate, LMH; microcrystalline cellulose, 
MCC; and Starch) and LMH, MCC and Starch-based protransfersome powder formulations (F1 – F27) 
were characterized via angle of repose (AOR), compressibility index, volume median diameter (VMD), 
SPAN, zeta potential and entrapment efficiency. Data are mean ± SD, n = 4 






















LMH 10.24 ± 1.22 13.85 ± 3.95 N/A N/A -3.68 ± 0.74 N/A 
MCC 18.65 ± 1.55 23.26 ± 2.67 N/A N/A -1.86 ± 0.38 N/A 
Starch 15.01 ± 1.16 20.469 ± 3.18 N/A N/A -11.65 ± 2.16 N/A 
F1 18.45 ± 1.16 9.79 ± 0.65 5.34 ± 0.77 3.88 ± 0.85 -2.44 ± 0.54 97.25 ± 3.18 
F2 15.06 ± 1.22 11.33 ± 0.66 6.53 ± 0.67 3.82 ± 0.65 -3..7 ± 1.21 96.61 ± 4.21 
F3 13.16 ± 0.81 12.21 ± 0.54 5.65 ± 0.85 2.51 ± 0.62 -2.39 ± 0.44 96.55 ± 3.47 
F4 19.03 ± 1.56 9.88 ± 0.65 5.83 ± 0.56 4.06 ± 0.85 -3.17 ± 1.13 96.02 ± 4.61 
F5 16.75 ± 1.21 11.24 ± 0.52 6.06 ± 0.49 3.76 ± 0.68 -3.46 ± 0.85 97.53 ± 3.88 
F6 14.01 ± 1.03 12.06 + 0.31 6.76 ± 0.61 3.75 ± 0.55 -3.09 ± 0.60 96.26 ± 3.17 
F7 18.75 ± 1.46 9.77 ± 0.38 5.66 ± 0.72 3.65 ± 0.77 -3.02 ± 0.92 94.87 ± 4.56 
F8 15.24 ± 1.55 11.45 ± 0.44 6.51 ± 0.62 3.44 ± 0.67 -2.41 ± 0.46 92.68 ± 3.68 
F9 13.62 ± 1.14 12.50 ± 0.73 6.46 ± 0.73 4.11 ± 0.96 -3.04 ± 0.66 93.03 ± 4.37 
F10 26.45 ± 1.42 19.75 ± 1.20 9.56 ± 1.29 2.85 ± 0.89 -3.28 ± 0.78 94.11 ± 4.15 
F11 23.48 ± 1.67 20.46 ± 0.85 10.56 ± 0.72 3.76 ± 0.77 -4.03 ± 0.84 96.94 ± 4.01 
F12 20.21 ± 1.12 22.79 ± 1.16 9.88 ± 0.91 3.63 ± 0.79 -3.84 ± 1.47 95.60 ± 3.05 
F13 27.09 ± 1.85 18.87 ± 0.83 9.55 ± 1.06 3.76 ± 0.88 -2.52 ± 0.55 97.81 ± 3.17 
F14 23.88 ± 1.65 20.68 ± 1.78 10.65 ± 0.88 2.99 ± 0.67 -2.18 ± 1.04 95.66 ± 3.89 
F15 21.22 ± 1.10 21.26 ± 1.84 10.72 ± 0.76 3.81 ± 0.77 -3.42 ± 0.95 96.41 ± 4.24 
F16 26.97 ± 1.55 19.34 ± 1.53 9.82 ± 1.61 3.45 ± 0.68 -3.14 ± 0.76 92.04 ± 4.56 
F17 22.84 ± 1.68 22.16 ± 1.66 9.80 ± 1.46 3.80 ± 0.55 -2.98 ± 1.25 92.86 ± 4.97 
F18 20.57 ± 1.23 22.89 ± 1.73 10.26 ± 0.95 3.56 ± 0.75 -3.42 ± 0.73 93.03 ± 3.93 
F19 24.26 ± 1.22 16.25 ± 1.42 11. 02 ± 1.06 4.46 ± 1.26 -3.70 ± 1.35 94.90 ± 4.01 
F20 20.27 ± 1.31 18.46 ± 1.61 12.56 ± 1.41 4.36 ± 1.33 -4.10 ± 1.20 97.16 ± 3.17 
F21 18.53 ± 0.82 21.34 ± 1.76 9.56 ± 0.95 3.22 ± 0.74 -3.58 ± 1.05 96.62 ± 4.57 
F22 23.73 ± 1.17 16.91 ± 1.72 10.68 ± 0.86 4.45 ± 1.49 -3.91 ± 0.94 95.70 ± 3.16 
F23 20.44 ± 1.26 19.65 ± 1.85 9.62 ± 1.05 3.46 ± 0.76 -4.23 ± 1.67 97.05 ± 3.97 
F24 19.30 ± 1.03 21.19 ± 1.79 10.16 ± 0.79 3.73 ± 0.82 -3.09 ± 0.83 96.78 ± 4.54 
F25 25.68 ± 1.65 16.91 ± 1.75 11.39 ± 0.88 3.96 ± 077 -3.23 ± 0.97 94.92 ± 3.77 
F26 24.13 ± 1.95 18.68 ± 1.69 9.82 ± 1.12 2.33 ± 0.86 -3.52 ± 0.89 94.96 ± 4.62 
F27 22.12 ± 1.11 22.39 ± 1.86 10.76 ± 1.31 4.23 ± 1.23 -4.76 ± 1.33 93.81 ± 3.30 
* Flow properties of powder employing angle of repose (AOR) and compressibility index (CI) via Carr’s scale of 
flowability (Carr, 1965) show the following flow character; excellent (25-30 AOR, 1-10 CI), good (31-35 AOR, 
11-15 CI), fair (36-40 AOR, 16-20 CI), passable (41-45 AOR, 21-25 CI), poor (46-55 AOR, 26-31 CI), very poor 









Table 3. Micro transfersomes vesicles suspensions of formulations (i.e. F3, F6 and F9) were probe 
sonicated in order to reduce the size in nanometre range (i.e. F3N, F6N and F9N) (followed by their 
characterization). Nano suspensions were then converted into dry protransfersome powder via spray 
drying (SD) (i.e. F3NSD, F6NSD and F9NSD) or freeze drying (FD) (i.e. F3NFD, F6NFD and F9NFD) to 
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investigate production yield and angle of repose (AOR) analysis. These Nano SD or Nano FD 
protransfersome powder formulations were rehydrated into transfersome suspension for volume 
median diameter (VMD), polydispersity index (PDI) and zeta potential analysis. Data are mean ± SD, 
n = 4 
Formulations VMD 
(nm) 









   
F3N 254.36 ± 5.64 0.382 ± 0.67 -2.55 ± 0.65 n/a n/a 
F6N 458.92 ± 7.78 0.330 ± 0.73 -2.49 ± 0.74 n/a n/a 




   
F3NSD 261.51 ± 6.85 0.421 ± 0.54 -2.67 ± 0.62 57.94 ± 2.86 46.65 ± 2.06 
F6NSD 465.85 ± 6.89 0.397 ± 0.61 -2.53 ± 0.75 60.99 ± 3.88 49.68 ± 1.62 




   
F3NFD 292.16 ± 5.43 0.451 + 0.71 -2.55 ± 0.76 93.52 ± 3.12 - 
F6NFD 483.62 ± 5.67 0.434 + 0.69 -2.61 ± 0.68 93.48 ± 3.62 - 

















Table 4. Quality control tests including; weight uniformity, crushing strength, tablets thickness and 
disintegration time for Micro protransfersome tablets formulations (i.e. F3, F6 and F9) as well as for 
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Nano spray dried (SD) protransfersome tablets formulations (i.e. F3NSD, F6NSD and F9NSD). Data are 
mean ± SD, n = 4 








F3 138.64 ± 6.85 17.54 ± 2.15 2.62 ± 0.41 13.54 ± 1.64 
F6 141.76 ± 5.28 18.36 ± 2.82 2.58 ± 0.34 12.43 ± 1.71 
F9 135.89 ± 6.74 17.52 ± 2.16 2.67 ± 0.39 14.57 ± 1.62 
     
F3NSD 111.46 ± 5.46 10.52 ± 1.26 1.72 ± 0.28 7.64 ± 1.06 
F6NSD 103.32 ± 6.71 11.42 ± 1.56 1.83 ± 0.24 8.66 ± 1.54 
























Table 5. Micro protransfersome tablet formulations (i.e. F3, F6 and F9) were aerosolized via Ultrasonic 
and Omron (i.e. Vibrating mesh) nebulizer for nebulization time, sputtering time, mass output and output 
rate. Data are mean ± SD, n = 4  














Ultrasonic     
F3 8.53 ± 2.81 2.42 ± 0.32 92.77 ± 3.72 460.33 ± 10.65 
F6 9.15 ± 2.66 2.37 ± 0.21 90.65 ± 4.51 445.86 ± 12.52 
F9 8.95 ± 2.44 2.62 ± 0.28 93.26 ± 4.18 464.42 ± 10.72 
Omron     
F3 21.56 ± 2.51 1.62 ± 0.23 96.66 ± 3.75 200.67 ± 9.84 
F6 23.12 ± 2.66 1.38 ± 0.29 97.18 ± 2.62 190.42 ± 8.50 





























Figures 1. Images of coarse carbohydrate carriers i.e. (a) lactose monohydrate, LMH, (b) 
microcrystalline cellulose, MCC and, (c) Starch; for protransfersome powder formulations. These 





























Figure 2. TEM images of transfersomes vesicles generated from (1:25 w/w lipid phase to carrier ratios) 
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Figure 3: Viability of MRC-5 and MRC-5 SV2 cell lines tested with transfersome generated from 
protransfersome tablet formulations F3, F6 and F9 using both PTX-free and PTX-loaded in black, flat-
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